主页 > 医药科学 >
【medical-news】生物梅里埃公司检测 NT-proBNP方法获
March 20, 2008 (Rockville, MD) - The FDA has granted market clearance to the automated VIDAS NT-proBNP assay for measuring serum or plasma levels of the N-terminal fragment of B-type natriuretic peptide (NT-proBNP), the test's manufacturer, bioMérieux, has announced [1].
The approval was based on the agency's determination that the assay is substantially equivalent to the Elecsys proBNP assay from Roche Diagnostics [2], which is used in emergency departments to help distinguish acute heart failure from syndromes with similar presentations. The bioMérieux test is an enzyme-linked fluorescent assay developed under a licensing agreement with Roche; the latter company's assay is based on electrochemiluminescence.
http://www.medscape.com/viewarticle/571777 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-07 15:46
医学,生命科学网